Millicent Embry

2.0k total citations
12 papers, 421 citations indexed

About

Millicent Embry is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Millicent Embry has authored 12 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Millicent Embry's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Multiple Myeloma Research and Treatments (3 papers) and HER2/EGFR in Cancer Research (3 papers). Millicent Embry is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Multiple Myeloma Research and Treatments (3 papers) and HER2/EGFR in Cancer Research (3 papers). Millicent Embry collaborates with scholars based in United States and Canada. Millicent Embry's co-authors include Katherine G. Rendahl, Natalie Nguyen, Yu Chen, Daniel Henderson, Dechao Yu, Yuanhao Li, Hong Zhang, Jeanette Dilley, Daniel E. Lopes de Menezes and Sylvia Ma and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Millicent Embry

10 papers receiving 407 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Millicent Embry United States 6 286 227 149 45 44 12 421
Phillip H. Koeffler United States 6 336 1.2× 205 0.9× 56 0.4× 45 1.0× 11 0.3× 13 467
Margaret Bell United Kingdom 11 435 1.5× 222 1.0× 80 0.5× 24 0.5× 108 2.5× 19 560
Haithem Barbour Canada 7 490 1.7× 176 0.8× 62 0.4× 43 1.0× 38 0.9× 9 671
Mark Wade United Kingdom 12 326 1.1× 140 0.6× 50 0.3× 40 0.9× 55 1.3× 24 478
Raymond E. Meyn United States 11 237 0.8× 142 0.6× 49 0.3× 30 0.7× 25 0.6× 15 385
C Chen United States 6 444 1.6× 238 1.0× 93 0.6× 14 0.3× 17 0.4× 7 495
Wilhelm Henning Germany 6 662 2.3× 419 1.8× 87 0.6× 63 1.4× 13 0.3× 6 764
Ivana Heřmanová Czechia 9 198 0.7× 97 0.4× 36 0.2× 37 0.8× 39 0.9× 16 406
C. Guha United States 4 231 0.8× 299 1.3× 58 0.4× 27 0.6× 9 0.2× 13 515

Countries citing papers authored by Millicent Embry

Since Specialization
Citations

This map shows the geographic impact of Millicent Embry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Millicent Embry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Millicent Embry more than expected).

Fields of papers citing papers by Millicent Embry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Millicent Embry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Millicent Embry. The network helps show where Millicent Embry may publish in the future.

Co-authorship network of co-authors of Millicent Embry

This figure shows the co-authorship network connecting the top 25 collaborators of Millicent Embry. A scholar is included among the top collaborators of Millicent Embry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Millicent Embry. Millicent Embry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Yuan, Robert, Andrew McGeehan, Sihong Zhou, et al.. (2025). The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death. Molecular Cancer Therapeutics. 24(9). 1428–1441. 1 indexed citations
2.
3.
Li, Xiaofan, Cristina L. Abrahams, Abigail Yu, et al.. (2023). Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001. Oncotarget. 14(1). 1–13. 5 indexed citations
4.
Abrahams, Cristina L., Xiaofan Li, Millicent Embry, et al.. (2018). Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001. Oncotarget. 9(102). 37700–37714. 45 indexed citations
5.
6.
Embry, Millicent, Xiaofan Li, Abigail Yu, et al.. (2017). CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug Conjugate, SΤRO-001. Blood. 130. 4420–4420. 1 indexed citations
7.
Molina, A., Amy S. Yu, Cristina L. Abrahams, et al.. (2017). STRO‐001, A NOVEL ANTI‐CD74 ANTIBODY DRUG CONJUGATE (ADC) FOR TREATMENT OF B‐CELL NON‐HODGKIN'S LYMPHOMAS (NHL). Hematological Oncology. 35(S2). 255–256. 1 indexed citations
8.
Abrams, Tinya J., Xiaohong Niu, Millicent Embry, et al.. (2015). Abstract 1695: Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML. Cancer Research. 75(15_Supplement). 1695–1695. 2 indexed citations
9.
Damiano, Jason S., Katherine G. Rendahl, Millicent Embry, et al.. (2012). Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer. Molecular Cancer Therapeutics. 12(3). 295–305. 49 indexed citations
10.
Tse, Archie, Katherine G. Rendahl, Tahir Sheikh, et al.. (2007). CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo. Clinical Cancer Research. 13(2). 591–602. 117 indexed citations
11.
Xin, Xiaohua, Tinya J. Abrams, Paul W. Hollenbach, et al.. (2006). CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice. Clinical Cancer Research. 12(16). 4908–4915. 53 indexed citations
12.
Yu, Dechao, Yu Chen, Jeanette Dilley, et al.. (2001). Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.. PubMed. 61(2). 517–25. 146 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Phillip H. Koeffler Breakdown of academic impact, for papers by Margaret Bell Breakdown of academic impact, for papers by Haithem Barbour Breakdown of academic impact, for papers by Mark Wade Breakdown of academic impact, for papers by Raymond E. Meyn Breakdown of academic impact, for papers by C Chen Breakdown of academic impact, for papers by Wilhelm Henning Breakdown of academic impact, for papers by Ivana Heřmanová Breakdown of academic impact, for papers by C. Guha
Rankless by CCL
2026